3 withdrawn, 2 completed, 2 unknown, 1 not yet recruiting. 9 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Withdrawn 3, Completed 2, Unknown 2, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 2 | Unknown 1, Withdrawn 1 |
Follow Histamine: new trials by email Literature Review of Histamine trials Research Report on Histamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge - Drug Allergy, Cephalosporin Allergy | Phase 2 | Recruiting | Massachusetts General Hospital | 300 | 2025-05-05 | 2026-11-12 |
| Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer Histamine Dihydrochloride (HDC), Interleukin-2 (IL-2) - Pancreatic Cancer, Surgery | Phase 2 | Not yet recruiting | Sahlgrenska University Hospital | 50 | 2024-04-01 | 2023-11-22 |
| Histaminergic Basis of Fatigue in Multiple Sclerosis L-Histidine, Placebo, Lodosyn - Multiple Sclerosis | Phase 2 | Withdrawn | University of Miami | 2022-01-01 | 2021-07-29 | |
| A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML) Cohort 1, Ceplene® and Proleukin®, Cohort 2, Ceplene® and Proleukin®, Cohort 3, Ceplene® and Proleukin® - Leukemia, Myelomonocytic, Chronic | Phase 1 / Phase 2 | Unknown | Vastra Gotaland Region | 15 | 2017-02-15 | 2017-12-19 |
| Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP) Hyaluronidase, Histamine, Saline - Allergic Skin Reaction | Phase 2 | Completed | Amphastar Pharmaceuticals, Inc. | 253 | 2012-09-01 | 2017-01-20 |
| Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes Ceplene®, IL-2, Azacitidine, Azacitidine - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Withdrawn | Groupe Francophone des Myelodysplasies | 2011-03-01 | 2014-03-20 | |
| Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis. Live Hookworm Larvae, Histamine - Multiple Sclerosis | Phase 2 | Withdrawn | University of Nottingham | 2008-02-01 | 2012-06-14 | |
| An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate, Histamine - Rhinitis, Allergic, Seasonal | Phase 2 | Completed | Dynavax Technologies Corporation | 271 | 2007-09-01 | 2019-04-16 |
| Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer aldesleukin, histamine dihydrochloride - Kidney Cancer | Phase 2 | Unknown | The Christie NHS Foundation Trust | 1999-06-01 | 2013-09-20 |
Hypersensitivity (3) · Multiple Sclerosis (2) · Anaphylaxis (1) · Carcinoma, Renal Cell (1) · Drug Hypersensitivity (1) · Fatigue (1) · Kidney Neoplasms (1) · Leukemia, Myelomonocytic, Chronic (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Rhinitis, Allergic (1) · Rhinitis, Allergic, Seasonal (1)
Amphastar Pharmaceuticals, Inc. (1) · Dynavax Technologies Corporation (1) · Groupe Francophone des Myelodysplasies (1) · Massachusetts General Hospital (1) · Sahlgrenska University Hospital (1) · The Christie NHS Foundation Trust (1) · University of Miami (1) · University of Nottingham (1) · Vastra Gotaland Region (1)
United States (3) · United Kingdom (2) · Canada (1) · France (1) · Sweden (1)
Andreas Muth (1) · Cris Constantinescu, MD PhD (1) · David A Khan, MD (1) · Eduardo Martins, MD, DPhil (1) · Kimberly G Blumenthal, MD, MSc (1) · Kottil Rammohan, MD (1) · Mark R. Middleton, MD, PhD, MBChB, MRCP (1) · Pierre Fenaux, MD (1) · Selina Su, MPH (1)
U01AI184071 (1)